Recombinant activated FVIIa binds to tissue factor (TF) released at the site of tissue injury resulting in thrombin generation thus bypassing the need for FVIII.49,50 The European medicines Agency (EMEA) concluded that rFVIIa’s benefits are great for the treatment and prevention of bleeding episodes in patients with congenital haemophilia with inhibitors undergoing surgery, congenital factor VII deficiency and Glanzmann’s thrombasthenia. This evidence concerns the gene F8 and hemophilia.